Camp4 Therapeutics Poration Stock Fundamentals
| CAMP Stock | USD 5.90 0.93 18.71% |
CAMP4 THERAPEUTICS PORATION fundamentals help investors to digest information that contributes to CAMP4 THERAPEUTICS's financial success or failures. It also enables traders to predict the movement of CAMP4 Stock. The fundamental analysis module provides a way to measure CAMP4 THERAPEUTICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CAMP4 THERAPEUTICS stock.
At this time, CAMP4 THERAPEUTICS's Cost Of Revenue is relatively stable compared to the past year. As of 01/31/2025, Total Operating Expenses is likely to grow to about 93.1 M, while EBIT is likely to drop (20.3 M). CAMP4 | Select Account or Indicator |
CAMP4 THERAPEUTICS PORATION Company Net Income Analysis
CAMP4 THERAPEUTICS's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current CAMP4 THERAPEUTICS Net Income | (49.29 M) |
Most of CAMP4 THERAPEUTICS's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CAMP4 THERAPEUTICS PORATION is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
CAMP4 Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, CAMP4 THERAPEUTICS PORATION reported net income of (49.29 Million). This is 109.15% lower than that of the Communications Equipment sector and 118.45% lower than that of the Information Technology industry. The net income for all United States stocks is 108.63% higher than that of the company.
CAMP4 THERAPEUTICS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CAMP4 THERAPEUTICS's current stock value. Our valuation model uses many indicators to compare CAMP4 THERAPEUTICS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CAMP4 THERAPEUTICS competition to find correlations between indicators driving CAMP4 THERAPEUTICS's intrinsic value. More Info.CAMP4 THERAPEUTICS PORATION is rated third in price to earning category among its peers. It is rated below average in revenue category among its peers totaling about 584,581 of Revenue per Price To Earning. At this time, CAMP4 THERAPEUTICS's Total Revenue is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value CAMP4 THERAPEUTICS by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.CAMP4 Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CAMP4 THERAPEUTICS's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CAMP4 THERAPEUTICS could also be used in its relative valuation, which is a method of valuing CAMP4 THERAPEUTICS by comparing valuation metrics of similar companies.CAMP4 THERAPEUTICS is currently under evaluation in net income category among its peers.
CAMP4 THERAPEUTICS ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CAMP4 THERAPEUTICS's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CAMP4 THERAPEUTICS's managers, analysts, and investors.Environmental | Governance | Social |
CAMP4 Fundamentals
| Price To Earning | 318.57 X | ||||
| Revenue | 186.23 M | ||||
| EBITDA | (8.72 M) | ||||
| Net Income | (49.29 M) | ||||
| Cash And Equivalents | 47.72 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 178.68 M | ||||
| Current Ratio | 1.86 X | ||||
| Book Value Per Share | (45.01) X | ||||
| Cash Flow From Operations | (44.16 M) | ||||
| Earnings Per Share | (63.02) X | ||||
| Price To Earnings To Growth | 0.08 X | ||||
| Target Price | 14.18 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.89 | ||||
| Market Capitalization | 660.34 K | ||||
| Total Asset | 54.95 M | ||||
| Retained Earnings | (159.96 M) | ||||
| Working Capital | 32.21 M | ||||
| Current Asset | 298.77 M | ||||
| Current Liabilities | 49.56 M | ||||
| Net Asset | 54.95 M |
About CAMP4 THERAPEUTICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CAMP4 THERAPEUTICS PORATION's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CAMP4 THERAPEUTICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CAMP4 THERAPEUTICS PORATION based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 22.9 M | 23.9 M | |
| Total Revenue | 167.6 M | 217.1 M | |
| Cost Of Revenue | 107.3 M | 133.1 M | |
| Sales General And Administrative To Revenue | 0.15 | 0.10 | |
| Research And Ddevelopement To Revenue | 0.07 | 0.06 | |
| Revenue Per Share | 4.53 | 4.73 | |
| Stock Based Compensation To Revenue | 0.03 | 0.02 | |
| Capex To Revenue | 0.07 | 0.04 | |
| Ebit Per Revenue | (0.05) | (0.05) |
Pair Trading with CAMP4 THERAPEUTICS
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CAMP4 THERAPEUTICS position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CAMP4 THERAPEUTICS will appreciate offsetting losses from the drop in the long position's value.Moving against CAMP4 Stock
| 0.55 | CEROW | CERo Therapeutics Symbol Change | PairCorr |
| 0.53 | FULC | Fulcrum Therapeutics | PairCorr |
| 0.49 | FRTX | Fresh Tracks Therapeutics | PairCorr |
| 0.4 | VAXX | Vaxxinity | PairCorr |
| 0.4 | EPRX | Eupraxia Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to CAMP4 THERAPEUTICS could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CAMP4 THERAPEUTICS when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CAMP4 THERAPEUTICS - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CAMP4 THERAPEUTICS PORATION to buy it.
The correlation of CAMP4 THERAPEUTICS is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CAMP4 THERAPEUTICS moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CAMP4 THERAPEUTICS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CAMP4 THERAPEUTICS can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for CAMP4 Stock Analysis
When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.